Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.78 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.59 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | NCF1 | P14598 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4429235 | 1.00 | HRH3 (0.78) | HRH3HRH4ALDH1A1KDM4ECYP2D6 | |
| SCHEMBL1334239 | 0.98 | HRH3 (0.75) | HRH3HRH4ALDH1A1KDM4ECYP2D6 | |
| SCHEMBL302270 | 0.98 | HRH3 (0.74) | HRH3HRH4ALDH1A1KDM4ECYP2D6 | |
| SCHEMBL4277270 | 0.89 | HRH3 (1.00) | HRH3HRH4ALDH1A1KDM4ECYP2D6 | |
| SCHEMBL4764364 | 0.87 | HRH3 (0.78) | HRH3HRH4ALDH1A1KDM4ECYP2D6 | |
| SCHEMBL3242385 | 0.86 | HRH3 (0.68) | HRH3HRH4ALDH1A1KDM4ECYP2D6 | |
| Hydrochloric Acid SCHEMBL7468055 | 0.86 | HRH3 (0.95) | HRH3HRH4ALDH1A1KDM4ECYP2D6 | |
| SCHEMBL11201497 | 0.86 | HRH3 (0.94) | HRH3HRH4ALDH1A1KDM4ECYP2D6 | |
| SCHEMBL3241388 | 0.84 | HRH3 (0.74) | HRH3HRH4ALDH1A1KDM4ECYP2D6 | |
| SCHEMBL3240187 | 0.84 | HRH3 (0.66) | HRH3HRH4ALDH1A1KDM4EMBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465869-B1 | MODULATORS OF LXR | EXELIXIS PATENT CO LLC (US) | 2013-05-15 | — | — | EP | claimed |
| US-7998986-B2 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | claimed |
| EP-1465869-A4 | MODULATORS OF LXR | X CEPTOR THERAPEUTICS INC (US) | 2005-12-28 | — | — | EP | claimed |
| JP-2005536450-A | — | — | 2005-12-02 | — | — | JP | claimed |
| EP-1465869-A1 | MODULATORS OF LXR | X-Ceptor Therapeutics, Inc. (US) | 2004-10-13 | — | — | EP | claimed |
| US-20030181420-A1 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS, INC. | 2003-09-25 | — | — | US | claimed |
| WO-2003059884-A1 | MODULATORS OF LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-07-24 | — | — | WO | claimed |
| CN-109651334-B | Process for preparing substituted piperidinedione derivatives | 南京卡文迪许生物工程技术有限公司 | 2021-12-21 | — | — | CN | disclosed |
| CN-109651334-A | The preparation method of substituted piperidine dione derivative | 南京卡文迪许生物工程技术有限公司 | 2019-04-19 | — | — | CN | disclosed |
| EP-1465869-B1 | MODULATORS OF LXR | EXELIXIS PATENT CO LLC (US) | 2013-05-15 | — | — | EP | disclosed |
| US-7998986-B2 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS PATENT COMPANY LLC (US) | 2011-08-16 | — | — | US | disclosed |
| EP-1465869-A4 | MODULATORS OF LXR | X CEPTOR THERAPEUTICS INC (US) | 2005-12-28 | — | — | EP | disclosed |
| EP-1465869-A1 | MODULATORS OF LXR | X-Ceptor Therapeutics, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20030181420-A1 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | EXELIXIS, INC. | 2003-09-25 | — | — | US | disclosed |
| WO-2003059884-A1 | MODULATORS OF LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181420-A1 | Heterocyclic compounds, in particular N-substituted pyridones for modulating the activity of nuclear receptors | NR1H2, NR1H3, NCOA1 | HRH3 1248/4885HRH4 848/4885ALDH1A1 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.